Connect with us

Media OutReach

Johnson & Johnson launches The 3rd Opinion in Asia Pacific: a new term to elevate the patient voice in the lung cancer treatment journey

Published

6 months ago

on

  • Newly published research shows up to 77% of patients in Asia Pacific trust and rely on their physicians to decide their treatment for them despite 69% of physicians encouraging patients to engage in shared decision making1.
  • A new term, coined The 3rd Opinion, is designed to spark a social movement that empowers patients to recognize their vital role in shared decision-making, in a region that is disproportionately impacted by lung cancer2.

SINGAPORE –

According to newly published data on NSCLC patient preferences in Future Oncology, up to 77% of patients in Asia Pacific trust and rely on their physicians to decide their treatment for them despite 69% of physicians encouraging patients to engage in shared decision making[1]. Cultural norms around stigma, not questioning authority, and limited understanding of the disease can often be major barriers causing patients not to voice concerns or ask questions, even when healthcare professionals actively encourage their input.

“Being diagnosed with lung cancer is overwhelming. It’s natural for patients to seek clarity, often by pursuing a second opinion, to better understand their condition and treatment options. However, patients often hesitate to express their concerns and treatment goals, causing them to be overlooked in the decision-making process. By creating space for the patient’s own opinion, The 3rd Opinion, creates a new way of thinking about lung cancer treatment and empowers patients to find their voice,” said Anthony Elgamal, Vice President of Oncology, Johnson & Johnson Innovative Medicine Asia Pacific.

J&J IM Key Visual Reunion The 3rd Opinion

Lung cancer has the highest incidence and mortality rate of all cancers worldwide, with more than 2.5 million people diagnosed every year, and Asia makes up 63% of all patients[2]. Up to 85% of lung cancers are non-small cell lung cancer (NSCLC) and Asians are more prone to certain genetic mutations than the rest of the world. One of the most prevalent is a mutation known as EGFR where 30-40% of all NSCLC diagnoses are in Asia, compared to 10-15% in the United States and Europe[3][4][5]. Often being diagnosed at a late stage, less than 20% of people with these genetic mutations survive beyond five years[6], and up to 40% never get the chance to receive a subsequent therapy after first-line treatment.[7][8][9]

“With the disproportionately high prevalence of certain NSCLC mutations in Asia Pacific, we need to think differently about how we treat patients and what more we can achieve with the first treatment. Treatment options have become increasingly complex and clinical decision making should comprehensively consider disease characteristics, patient treatment goals and values, and aim for an individualized balance between survival, longer lasting disease control and side effects. When shared decision making includes all available options, the final decision can be made collaboratively,” said Prof James Chih-Hsin Yang, Director of National Taiwan University Cancer Center and key advocate for The 3rd Opinion initiative.

J&J IM Key Visual Wedding The 3rd Opinion

Mark Brooke, Chief Executive Officer of Lung Foundation Australia, co-author of the Future Oncology publication and an advocate of The 3rd Opinion agreed, “The physician and patient dynamic is one of trust, but we cannot rely on that alone. The consequence is a potential disconnect between the patient and their healthcare professional around treatment preferences and personal goals. For patients, they often want more time above all else – to witness life’s milestones, more moments with loved ones, and more opportunities to simply live. Patients need to be equipped with adequate disease and treatment information, so they can communicate what matters most to them”.

J&J IM Key Visual Grandchild The 3rd Opinion

The 3rd Opinion will be launched across multiple markets with educational resources, including a Lung Cancer Book of Answers in China, a patient empowerment video and various shared decision making tools across Asia Pacific to spark a social movement that encourages patients to confidently articulate their personal goals for treatment. The creation of a neologism, like The 3rd Opinion, ensures shared decision making becomes accepted into clinical practice and in turn fosters an environment where the doctor’s expertise and the patient goals come together to design the best treatment plan.

[1] Chee Khoon Lee et al. Navigating advanced lung cancer care, patient–physician alliance, cancer stigma, and psychosocial support in Asia-Pacific: perspectives from patients, caregivers, and physicians. DOI: 10.1080/14796694.2025.2499511

[2] Natia Jokhadze MD, Arunangshu Das MBBS, Don S. Dizon MD. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. Volume 74Issue 3CA: A Cancer Journal for Clinicians pages: 224-226 First Published online: April 4, 2024

[3] Keedy VL, et al. American Society of Clinical Oncology Provisional Clinical Opinion: Epidermal Growth Factor Receptor (EGFR) Mutation Testing for Patients with Advanced Non-Small-Cell Lung Cancer Considering First-Line EGFR Tyrosine Kinase Inhibitor Therapy. Journal of Clinical Oncology. 2011; 29(15): 2121-2127.

[4] Ellison G, et al. EGFR Mutation Testing in Lung Cancer: a Review of Available Methods and Their Use for Analysis of Tumour Tissue and Cytology Samples. Journal of Clinical Oncology. 2013; 66(2): 79-89.

[5] Korpanty G, et al. Biomarkers That Currently Affect Clinical Practice in Lung Cancer: EGFR, ALK, MET, ROS-1, and KRAS. Frontiers in Oncology. 2014; 4: 204.

[6] Bazhenova L, Minchom A, Viteri S, et al. Comparative clinical outcomes for patients with advanced NSCLC harboring EGFR exon 20 insertion mutations and common EGFR mutations. Lung Cancer. 2021;162:154-161.​

[7] Nieva J, Karia PS, Okhuoya P, et al. A real-world (rw) observational study of long-term survival (LTS) and treatment patterns after first-line (1L) osimertinib in patients (pts) with epidermal growth factor receptor (EGFR) mutation-positive (m) advanced non-small cell lung cancer [ESMO abstract 1344P]. Ann Oncol. 2023;34(suppl 2):S774 ​

[8] Lee JY, Mai V, Garcia M, et al. Treatment patterns and outcomes of first-line osimertinib-treated advanced EGFR mutated NSCLC patients: a real-world study [IASLC abstract EP08.02-082]. Presented at: IASLC 2022 World Lung Conference on Lung Cancer; August 6-9, 2022; Vienna, Austria.​

[9] Girard N, Leighl NB, Ohe Y, et al. Mortality among EGFR-mutated advanced NSCLC patients after starting frontline osimertinib treatment: a real-world, US attrition analysis. Presented at: the European Lung Cancer Congress; March 29-April 1, 2023; Copenhagen, Denmark. Poster 19P.​

Hashtag: #Johnson&Johnson

The issuer is solely responsible for the content of this announcement.

About The 3rd Opinion

“The 3rd Opinion”, the patients own opinion, is a new term that sparks a social movement in the lung cancer treatment journey – designed to elevate the patient voice and empower individuals to take an active role in shaping their treatment plan. By prioritizing shared decision-making between patients and healthcare professionals, this collaborative approach ensures that treatment choices are aligned to each patient’s goals, preferences and circumstances. This results in more informed decisions, greater patient satisfaction, and the best possible outcomes.

About Non-Small Cell Lung Cancer

Worldwide, lung cancer is one of the most common cancers, with NSCLC making up 80 to 85 percent of all lung cancer cases.[10], [11] The main subtypes of NSCLC are adenocarcinoma, squamous cell carcinoma, and large cell carcinoma.[12] Among the most common driver mutations in NSCLC are alterations in EGFR, which is a receptor tyrosine kinase controlling cell growth and division.[13] EGFR mutations are present in 10 to 15 percent of Western patients with NSCLC with adenocarcinoma histology and occur in 40 to 50 percent of Asian patients.[14], [15],[16],[17],[18],[19] EGFR ex19del or EGFR L858R mutations are the most common EGFR mutations.[20] The five-year survival rate for all people with advanced NSCLC and EGFR mutations treated with EGFR tyrosine kinase inhibitors (TKIs) is less than 20 percent. [21], [22] EGFR exon 20 insertion mutations are the third most prevalent activating EGFR mutation.[23] Patients with EGFR exon 20 insertion mutations have a real-world five-year overall survival (OS) of eight percent in the frontline setting, which is worse than patients with EGFR ex19del or L858R mutations, who have a real-world five-year OS of 19 percent.[24]By comparison, other common cancers, such as breast and prostate cancer have a 5-year real world OS of 90% and 97% respectively[25].

[10]The World Health Organization. Cancer. https://www.who.int/news-room/fact-sheets/detail/cancer. Accessed March 2025.

[11] American Cancer Society. What is Lung Cancer? https://www.cancer.org/content/cancer/en/cancer/lung-cancer/about/what-is.html. Accessed March 2025.

[12] Oxnard JR, et al. Natural history and molecular characteristics of lung cancers harboring EGFR exon 20 insertions. J Thorac Oncol. 2013 Feb;8(2):179-84. doi: 10.1097/JTO.0b013e3182779d18.

[13] Bauml JM, et al. Underdiagnosis of EGFR Exon 20 Insertion Mutation Variants: Estimates from NGS-based Real World Datasets. Abstract presented at: World Conference on Lung Cancer Annual Meeting; January 29, 2021; Singapore.

[14] The World Health Organization. Cancer. https://www.who.int/news-room/fact-sheets/detail/cancer. Accessed March 2025.

[15] American Cancer Society. What is Lung Cancer? https://www.cancer.org/content/cancer/en/cancer/lung-cancer/about/what-is.html. Accessed March 2025.

[16] Pennell NA, et al. A phase II trial of adjuvant erlotinib in patients with resected epidermal growth factor receptor-mutant non-small cell lung cancer. J Clin Oncol. 37:97-104.

[17] Burnett H, et al. Epidemiological and clinical burden of EGFR exon 20 insertion in advanced non-small cell lung cancer: a systematic literature review. Abstract presented at: World Conference on Lung Cancer Annual Meeting; January 29, 2021; Singapore.

[18] Zhang YL, et al. The prevalence of EGFR mutation in patients with non-small cell lung cancer: a systematic review and meta-analysis. Oncotarget. 2016;7(48):78985-78993.

[19] Midha A, et al. EGFR mutation incidence in non-small-cell lung cancer of adenocarcinoma histology: a systematic review and global map by ethnicity. Am J Cancer Res. 2015;5(9):2892-2911.

[20] American Lung Association. EGFR and Lung Cancer. https://www.lung.org/lung-health-diseases/lung-disease-lookup/lung-cancer/symptoms-diagnosis/biomarker-testing/egfr. Accessed March 2025.

[21] Howlader N, et al. SEER Cancer Statistics Review, 1975-2016, National Cancer Institute. Bethesda, MD, https://seer.cancer.gov/csr/1975_2016/, based on November 2018 SEER data submission, posted to the SEER web site.

[22] Lin JJ, et al. Five-Year Survival in EGFR-Mutant Metastatic Lung Adenocarcinoma Treated with EGFR-TKIs. J Thorac Oncol. 2016 Apr;11(4):556-65

[23] Arcila, M. et al. EGFR exon 20 insertion mutations in lung adenocarcinomas: prevalence, molecular heterogeneity, and clinicopathologic characteristics. Mol Cancer Ther. 2013 Feb; 12(2):220-9.

[24] Girard N, et al. Comparative clinical outcomes for patients with NSCLC harboring EGFR exon 20 insertion mutations and common EGFR mutations. Abstract presented at: World Conference on Lung Cancer Annual Meeting; January 29, 2021; Singapore.

[25] Surveillance, Epidemiology, and End Results (SEER) Program, National Cancer Institute, 2024.

About Johnson & Johnson

At Johnson & Johnson, we believe health is everything. Our strength in healthcare innovation empowers us to build a world where complex diseases are prevented, treated, and cured, where treatments are smarter and less invasive, and solutions are personal. Through our expertise in Innovative Medicine and MedTech, we are uniquely positioned to innovate across the full spectrum of healthcare solutions today to deliver the breakthroughs of tomorrow, and profoundly impact health for humanity.

Learn more at or at . Follow us at .

Related Topics:
Advertisement

Media OutReach

XTransfer Joins Forum Ekonomi Malaysia 2026

Published

10 hours ago

on

11/02/2026

By

Signals Plan to Make Malaysia Regional Compliance Hub

KUALA LUMPUR, MALAYSIA – Media OutReach Newswire – 11 February 2026 – XTransfer, the world’s leading B2B cross-border financial platform, was honoured to be invited to join the Malaysia Economic Forum (Forum Ekonomi Malaysia 2026). Bill Deng, Founder and CEO of XTransfer, shared insights on how Malaysia can accelerate technology application and innovation to help micro, small and medium enterprises (MSMEs) scale exports under the 13th Malaysia Plan (13MP), during FEM 2026’s panel discussion, “Made by Malaysia: Accelerating Technology Applications & Innovation”.

Bill Deng (second from the right), Founder and CEO of XTransfer, joins as a speaker at Forum Ekonomi Malaysia 2026.

Bill was honoured to join YB Tuan Liew Chin Tong, Deputy Minister of Finance of Malaysia, and Mr Ooi Ching Liang, Senior Director of Engineering at SkyeChip, for a discussion focused on strengthening high-growth, high-value industries, advancing R&D commercialisation, increasing productivity and competitiveness, and supporting MSMEs in global value chains.

Drawing on XTransfer’s work with MSMEs across markets, Bill noted that many Malaysian businesses are “able to export,” but face persistent barriers to scaling exports. The most common issues are trust, compliance, and scale, which often surface as payment delays, repeated documentation requests, FX uncertainty, and working capital pressure as orders grow.

“For B2B SMEs in foreign trade, the biggest constraint isn’t demand. It’s the operational complexity behind cross-border payments, foreign exchange, and compliance,” Bill said. “In particular, AML requirements can be difficult for both traditional banks and SMEs to manage efficiently, creating friction that slows down legitimate trade.”

Bill highlighted a structural shift in global trade flows from a single dominant corridor to non-U.S., intra-Asia, and broader South–South routes. This trend is increasingly clear in real SME transaction patterns. Bill shared, “In 2025, XTransfer’s average collection amount from Asia, Africa, and Latin America grew by 106% year-on-year, with Africa exceeding 270%, Latin America reaching 94%, and ASEAN reaching 82%.” YB Liew noted the trend and thinks it is a direction Malaysia should pursue.

XTransfer also said it plans to establish Malaysia as its regional compliance centre, citing Malaysia’s strong geographic and time-zone advantages, a mature regulatory environment, availability of talent in compliance and risk operations, and cost efficiency. “Malaysia gives us the talent, governance environment, and regional proximity to scale compliance as intra-Asia and emerging-market trade accelerates,” Bill added.
Hashtag: #XTransfer #Malaysia #SMEs #13MP #FEM2026




The issuer is solely responsible for the content of this announcement.

Continue Reading

Media OutReach

CGTN: Little Chinese New Year opens big window to China’s soul

Published

10 hours ago

on

11/02/2026

By

BEIJING, CHINA – Media OutReach Newswire – 11 February 2026 – As China marks Xiaonian, or Little Chinese New Year, there is growing evidence of its ancient traditions evolving into global lifestyle trends. CGTN published an article analyzing how this prelude to the Year of the Horse – from the folk ritual of “sweeping the dust” to the cross-cultural fusion of the Spring Festival Gala – illustrates China’s growing global cultural resonance.

As the lunar calendar turns its final pages, China enters a period of joyful anticipation known as Xiaonian, or Little Chinese New Year. Often celebrated as the Festival of the Kitchen God, it marks the official start of the “busy year” – a traditional term for the intense, joyful period of preparing food, cleaning homes, and shopping for the upcoming Spring Festival.

The Spring Festival is a deeply significant time for family reunion. In 2024, UNESCO inscribed the “Spring Festival, social practices of the Chinese people in celebration of the traditional Chinese New Year” onto the Representative List of the Intangible Cultural Heritage of Humanity.

While daily routines continue to evolve, they remain anchored in rituals that provide a sense of normalcy and meaning. It is perhaps no wonder that in a climate of uncertainty, traditional Chinese lifestyles are finding a new audience beyond the country’s borders, with the Spring Festival chief among those unique traditions that are fast becoming a shared human experience.

Diverse traditions, shared aspirations

In a prelude to the broader celebrations, Xiaonian, observed on February 10 and 11 this year, kickstarts a focused period of preparation. According to ancient lore, families offer Zaotang, or sticky “Kitchen Candy,” to the Kitchen God to ensure he delivers a favorable report on the household’s conduct before he ascends to the heavens. This lighthearted tradition marks the beginning of several symbolic rituals aimed at welcoming a fresh start.

A key element of this transition is donning new clothes. In Chinese culture, the New Year represents a moment when “all things are renewed,” and wearing new garments symbolizes shedding the “dust” or misfortunes of the past to embrace auspicious energy for the year ahead. Alongside this personal renewal, families nationwide engage in “sweeping the dust,” a deep-cleaning ritual to purify the home and prepare it for new blessings.

Whereas these practices are universal, celebratory flavors vary by geography. In the north, families traditionally gather over steaming plates of dumplings, whereas in the south, the menu often features sweet rice cakes (Niangao) and glutinous rice balls (Tangyuan).

As Mao Qiaohui, a researcher at the Institute of Ethnic Literature at the Chinese Academy of Social Sciences, explains, these variations highlight the inclusive nature of Chinese civilization.

“Although folk customs differ between different regions across China, this diversity reflects the cultural pluralism within the Spring Festival tradition,” she notes. “Different regional identities contribute to a shared pursuit of harmony and reunion.”

The vitality of these traditions is also evident in local craftsmanship. In northern regions like Shandong and Henan, artisans are currently making Huamo, decorated steamed buns, featuring horse designs for the upcoming zodiac year. Meanwhile, in Shuozhou, Shanxi Province, intangible heritage inheritors are carving spirited stallions onto traditional gourds. These creations reflect the regional diversity of the festival and a collective desire for progress in the year ahead.

Cultural dialogue: From global stage to daily life

The festive atmosphere is reflected further in preparations for the Spring Festival Gala (Chunwan), produced by China Media Group.

Recent rehearsals show performances meshing traditional Chinese culture with international artistry. One performance piece combines the wooden clog dance of the Hani and Lisu ethnic groups with the rhythmic tap of Spanish Flamenco and Hungarian folk dance. And with global stars like Jackie Chan and Lionel Richie on the bill, the Gala’s stage is set to become a stage for the world to come together.

The reach of the gala has expanded far beyond a domestic audience. Through the “Spring Festival Gala Prelude” events held in the United States, Russia, France, Italy, and several African nations, the program has become a gateway to Chinese New Year customs and cultural exchange.

This interest extends beyond art and into the lives of people worldwide, as seen in the #BecomingChinese trend. This phenomenon features international social media users adopting elements of Chinese daily life – such as keeping a thermos of hot water handy, wearing quilted indoor slippers or practicing mindful movement with Baduanjin exercises.

The festival is no longer a distant event but a gateway to Chinese lifestyle, rooted in ancient wellness wisdom and constantly updated by modern convenience, and the first step to a journey of exploration into a culture that values ritual, safety and hospitality.

Whether through global broadcasts or shared daily habits, the Spring Festival increasingly strengthens a sense of cultural empathy between China and the rest of the world.

For more information, please click here:

https://news.cgtn.com/news/2026-02-10/Little-New-Year-opens-big-window-to-China-s-soul-1KEhJjMX2fe/p.html

Hashtag: #CGTN

The issuer is solely responsible for the content of this announcement.

Continue Reading

Media OutReach

De Beers Group and Assouline Celebrate the Launch of “A Diamond Is Forever: The Making of A Cultural Icon 1926-2026”

Published

11 hours ago

on

11/02/2026

By

LONDON, UK – Media OutReach Newswire – 11 February 2026 – In the 1930s, De Beers redefined the role of diamonds in society, celebrating them as masterpieces of nature and craftmanship. Before this, diamond jewelry pieces were treasures exchanged discreetly amongst society’s elite, as luxury houses, fearful of diminishing their mystique, fostered only private relationships with their clients. De Beers revealed the wonder of diamonds to a wider audience, shifting the perception of them from luxury item to a gift integral to romantic milestones and aspirational, glamorous lives, as well as a way of marking personal achievement.

De Beers Group And Assouline Celebate The Launch Of “A Diamond Is Forever: The Making Of A Cultural Icon 1926-2026”

When copywriter Frances Gerety captured the diamond’s essence with the phrase “A Diamond Is Forever” in 1947, the declaration enshrined the diamond as a promise of love and endurance, a sentiment resonating far beyond the notion of a simple gift. Gerety’s words, seen on archival advertisements, magazine placements, and celebrity endorsements, reflected the deep cultural connection between diamonds and enduring relationships. Commissioned artwork from artists such as Pablo Picasso, Salvador Dalí, and Raoul Dufy draw a direct line between a diamond’s rarity—each one formed deep within the earth over billions of years—and the creative genius of fine art. By sharing these artistic visions with the world, De Beers revealed the wonder of diamonds—nature’s oldest treasure—to a wider audience, elevating their aura and allure while preserving the sense of rarity and significance that sets them apart.

For a century, the story of diamonds has been one of transformation and continuity. In the 1960s, stars like Elizabeth Taylor and Marilyn Monroe adorned themselves with diamonds, embodying the elegance and glamour associated with the gemstone. The 1990s “Shadows” campaign, with its evocative pairing of diamonds and the neoclassical composition Palladio by Karl Jenkins, captured the essence of the diamond: authentic, unique, and everlasting.

In recent years, the conversation around diamonds has expanded to include provenance, sustainability, and ethical stewardship, affirming the diamond’s place as a symbol not just of love but of responsibility and conscience. Much like walking through a gallery that traces the evolution of artistic expression, A Diamond Is Forever offers a view into how diamonds have come to embody the shifting ideals and aspirations of society itself.

Hashtag: #DeBeersGroup #NaturalDiamonds #diamonds #ADiamondIsForever #Assouline




The issuer is solely responsible for the content of this announcement.

About De Beers Group

Established in 1888, De Beers Group is the world’s leading diamond company with expertise in the exploration, mining, marketing and retailing of diamonds. Together with its joint venture partners, De Beers Group employs more than 20,000 people across the diamond pipeline and is the world’s largest diamond producer by value, with diamond mining operations in Botswana, Canada, Namibia and South Africa. Innovation sits at the heart of De Beers Group’s strategy as it develops a portfolio of offers that span the diamond value chain, including its jewellery houses, De Beers Jewellers and Forevermark, and other pioneering solutions such as diamond sourcing and traceability initiatives Tracr and GemFair. De Beers Group also provides leading services and technology to the diamond industry in the form of education and laboratory services via De Beers Institute of Diamonds and a wide range of diamond sorting, detection and classification technology systems via De Beers Group Ignite. De Beers Group is committed to ‘,’ a holistic and integrated approach for creating a better future – where safety, human rights and ethical integrity continue to be paramount; where communities thrive and the environment is protected; and where there are equal opportunities for all. De Beers Group is a member of the Anglo American plc group. For further information, visit .

Continue Reading

Trending